Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2016 May;101(5):1931-4.
doi: 10.1210/jc.2016-1097. Epub 2016 Mar 16.

Novel Management of Insulin Autoimmune Syndrome with Rituximab and Continuous Glucose Monitoring

David R Saxon  1 , Michael T McDermott  1 , Aaron W Michels  1
Affiliations
Case Reports

Novel Management of Insulin Autoimmune Syndrome with Rituximab and Continuous Glucose Monitoring

David R Saxon et al. J Clin Endocrinol Metab. 2016 May.

Abstract

Context: Insulin autoimmune syndrome (IAS), or Hirata's disease, is a rare hypoglycemic disorder characterized by spontaneous hypoglycemia without evidence of exogenous insulin administration, a high serum concentration of total immunoreactive insulin, and the presence of insulin autoantibodies in high titer. The majority of cases occur in the Asian population, and treatment is generally successful with watchful waiting or steroids.

Case description: We report the case of a 71-year-old Caucasian man with severe hypoglycemia due to IAS that was refractory to a prolonged course of high-dose steroids. Type 1 diabetes prevention trials using rituximab have shown selective suppression of insulin autoantibodies, which are the pathogenic antibodies in IAS, and therefore we provided this therapy. Treatment with two doses of rituximab and daily use of a continuous glucose monitor resulted in disease remission.

Conclusion: We present the first case where potentially life-threatening hypoglycemia due to IAS was successfully managed with rituximab and a continuous glucose monitor. We conclude that these treatment modalities are effective for the management of severe, refractory IAS.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Clinical course showing prednisone dose and IAA levels over 67 weeks. Important clinical events highlighted include disease relapse (A), first rituximab dose (B), and second rituximab dose (C).
See this image and copyright information in PMC

References

    1. Hirata Y, Ishizu H, Ouchi N, et al. . Insulin autoimmunity in a case of spontaneous hypoglycemia. J Japan Diab Soc. 1970;13:312–320.
    1. Uchigata Y, Hirata Y. Insulin autoimmune syndrome (IAS, Hirata Disease). In: Eisenbarth G, ed. Molecular Mechanisms of Endocrine and Organ Specific Autoimmunity. Austin, TX: RG Landes; 1999:133–148.
    1. Uchigata Y, Kuwata S, Tokunaga K, et al. . Strong association of insulin autoimmune syndrome with HLA-DR4. Lancet. 1992;339:393–394. - PubMed
    1. Lupsa BC, Chong AY, Cochran EK, Soos MA, Semple RK, Gorden P. Autoimmune forms of hypoglycemia. Medicine. 2009;88:141–153. - PubMed
    1. Uchigata Y, Eguchi Y, Takayama-Hasumi S, Omori Y. Insulin autoimmune syndrome (Hirata disease): clinical features and epidemiology in Japan. Diabetes Res Clin Pract. 1994;22:89–94. - PubMed

Publication types